Streetbeat News

Analyst Ratings

LSTA

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Lisata Therapeutics (NASDAQ:LSTA) and maintained a $15 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 4:03 pm

PED

EF Hutton analyst Ignacio Bernaldez maintains a 'Buy' rating on PEDEVCO (AMEX:PED), but has lowered the price target from $2.75 to $2.5.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 4:01 pm

TSE

Trinseo (NYSE:TSE) has received one bullish and three indifferent analyst ratings in the last quarter. The average price target is $18.5, representing an upside from the current price of $12.665. This average price target is a 10.84% decrease from the previous average of $20.75.

Portfolio Pulse from Benzinga Insights

August 15, 2023 | 4:00 pm

THG

Hanover Insurance Gr (NYSE:THG) has received two somewhat bullish and two indifferent analyst ratings in the last quarter. The average 12-month price target for the company, according to four analysts, is $140.75, a decrease of 5.96% from the previous average price target of $149.67.

Portfolio Pulse from Benzinga Insights

August 15, 2023 | 4:00 pm

MBIO

Mustang Bio (NASDAQ:MBIO) has received four bullish ratings from analysts in the last quarter. The company's average 12-month price target is $21.5, with a high of $25.00 and a low of $16.00. This average price target has increased by 79.17% over the past month.

Portfolio Pulse from Benzinga Insights

August 15, 2023 | 4:00 pm

SUI

Analysts have provided various ratings for Sun Communities (NYSE:SUI) within the last quarter, with 1 bullish, 5 somewhat bullish, and 1 indifferent. The company has an average price target of $154.71, a 2.33% decrease from the previous average price target of $158.40.

Portfolio Pulse from Benzinga Insights

August 15, 2023 | 4:00 pm

PHR

Phreesia (NYSE:PHR) has received 8 analyst ratings in the last quarter, with 1 being bullish, 6 somewhat bullish, and 1 indifferent. The average price target is $37.88, representing an upside from the current price of $28.59. This average price target is a decrease of 11.91% from the previous average of $43.00.

Portfolio Pulse from Benzinga Insights

August 15, 2023 | 4:00 pm

EQIX

Equinix (NASDAQ:EQIX) has received 11 analyst ratings in the last quarter, with 6 being bullish, 1 somewhat bullish, and 4 indifferent. The average price target is $810.0, indicating an upside from the current price of $769.47. The average price target has increased by 3.14% over the past month.

Portfolio Pulse from Benzinga Insights

August 15, 2023 | 4:00 pm

NVDA

UBS analyst Timothy Arcuri has maintained a Buy rating on Nvidia Corp (NASDAQ:NVDA) and raised the price target from $475 to $540. Arcuri has substantially raised estimates ahead of Nvidia's earnings next week, with a Q3 revenue projection of $14.5 billion. He also sees Nvidia's EPS tracking to ~$10 this year and ~$17 in FY25. Wells Fargo analyst Aaron Rakers reiterated Nvidia with an Overweight and raised the price target from $450 to $500.

Portfolio Pulse from Anusuya Lahiri

August 15, 2023 | 3:53 pm

ARCT

HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Arcturus Therapeutics (NASDAQ:ARCT) and maintained a $51 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 3:52 pm